FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 150 filers reported holding FATE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $467,000 | -24.3% | 20,820 | +100.0% | 0.05% | -37.8% |
| Q3 2021 | $617,000 | +14.9% | 10,410 | +68.2% | 0.07% | +37.0% |
| Q2 2021 | $537,000 | -17.9% | 6,190 | -21.9% | 0.05% | -27.0% |
| Q1 2021 | $654,000 | +116.6% | 7,927 | -9.9% | 0.07% | +64.4% |
| Q2 2020 | $302,000 | -42.9% | 8,798 | -67.4% | 0.04% | -47.1% |
| Q4 2019 | $529,000 | +192.3% | 27,025 | +161.9% | 0.08% | +183.3% |
| Q1 2019 | $181,000 | +82.8% | 10,317 | -52.4% | 0.03% | +30.4% |
| Q1 2017 | $99,000 | – | 21,654 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |